Skip to main content

Table 3 Correlation between NLR value with clinicopathological features in prostate cancer

From: Correlation between peripheral blood neutrophil-lymphocyte ratio and CD34 expression in prostate cancer

Patients and tumor characteristics n(%) NLR χ2 P-value
≤3.3 >3.3
PSA level (ng/ml)
  < 10 19 (25.3) 12 (63.2) 7 (36.8) 8.248 0.016
 10 ~ 20 29 (38.7) 14 (48.3) 15 (51.7)   
  > 20 27 (36.0) 6 (22.2) 21 (77.8)   
Gleason score
  ≤ 6 14 (18.7) 10 (71.4) 4 (28.6) 6.797 0.033
 7 28 (37.3) 12 (42.9) 16 (57.1)   
 8 ~ 10 33 (44.0) 10 (30.3) 23 (69.7)   
T stage
 T1–2 33 (44.0) 21 (63.6) 12 (36.4) 10.593 0.001
 T3–4 42 (56.0) 11 (26.2) 31 (73.8)   
Lymph node metastasis
 N0 46 (61.3) 27 (58.7) 19 (41.3) 12.495 0.000
 N1 29 (38.7) 5 (17.2) 24 (82.8)   
Distant metastasis
 M0 43 (57.3) 25 (58.1) 18 (41.9) 9.863 0.002
 M1 32 (42.7) 7 (21.9) 25 (78.1)   
TNM stage
 Stage II 26 (34.7) 17 (65.4) 9 (34.6) 8.396 0.004
 Stage III ~ IV 49 (65.3) 15 (30.6) 34 (69.4)   
  1. NLR neutrophil-to-lymphocyte ratio, PSA prostate specific antigen